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Background: Type 2 diabetes is a major risk factor for chronic kidney disease, which substantially increases the risk
of cardiovascular disease mortality. This Phase IIb safety study (AleNephro) in patients with stage 3 chronic kidney
disease and type 2 diabetes, evaluated the renal effects of aleglitazar, a balanced peroxisome proliferator-activated
receptor-α/γ agonist.
Methods: Patients were randomized to 52 weeks’ double-blind treatment with aleglitazar 150 μg/day (n = 150)
or pioglitazone 45 mg/day (n = 152), followed by an 8-week off-treatment period. The primary endpoint was
non-inferiority for the difference between aleglitazar and pioglitazone in percentage change in estimated glomerular
filtration rate from baseline to end of follow-up. Secondary endpoints included change from baseline in estimated
glomerular filtration rate and lipid profiles at end of treatment.
Results: Mean estimated glomerular filtration rate change from baseline to end of follow-up was –2.7% (95% confidence
interval: –7.7, 2.4) with aleglitazar versus –3.4% (95% confidence interval: –8.5, 1.7) with pioglitazone, establishing
non-inferiority (0.77%; 95% confidence interval: –4.5, 6.0). Aleglitazar was associated with a 15% decrease in estimated
glomerular filtration rate versus 5.4% with pioglitazone at end of treatment, which plateaued to 8 weeks and was not
progressive. Superior improvements in high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and
triglycerides, with similar effects on glycosylated hemoglobin were observed with aleglitazar versus pioglitazone. No
major safety concerns were identified.
Conclusions: The primary endpoint in AleNephro was met, indicating that in stage 3 chronic kidney disease patients
with type 2 diabetes, the decrease in estimated glomerular filtration rate after 52 weeks’ treatment with aleglitazar
followed by 8 weeks off-treatment was reversible and comparable (non-inferior) to pioglitazone.
Trial registration: NCT01043029 January 5, 2010.
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Type 2 diabetes (T2D) increases the risk of cardio-
vascular (CV) disease and microvascular complications,
including diabetic nephropathy [1]. Multiple CV risk
factors—including hypertension, dyslipidemia, insulin
resistance and vascular inflammation–drive vascular risk in
patients with T2D, necessitating comprehensive manage-
ment strategies [2-4]. A multifactorial approach to treat-
ment of T2D, including lifestyle intervention, control of
glycosylated hemoglobin (HbA1c), low-density lipoprotein
cholesterol, blood pressure (including renin–angiotensin–
aldosterone system [RAAS] inhibition), insulin resistance
and low-grade inflammation, significantly reduces CV
events, but considerable CV risk remains [5,6].
Aleglitazar is designed to work through balanced acti-
vation of peroxisome proliferator-activated receptors
(PPARs)-α and -γ to improve insulin sensitivity, dyslipid-
emia and inflammation [7-9]. In the SYNCHRONY study
[9], a daily dose of 150 μg aleglitazar over 16 weeks signifi-
cantly improved HbA1c, fasting plasma glucose (FPG) and
the lipid profile, whilst ameliorating inflammatory markers
in patients with T2D and normal renal function. Aleglita-
zar at this dose was well tolerated, with a similar incidence
of adverse events compared with placebo [9]. However, a
non-progressive, dose-related increase in serum creatinine
(SCr) was observed during aleglitazar treatment, with a
corresponding decrease in estimated glomerular filtration
rate (eGFR) [9]. The significance of these effects for kidney
function was investigated further in a dedicated renal
function study (SESTA R) [10], which evaluated the effects
of a supratherapeutic dose of aleglitazar (600 μg/day for
6 months) on measured GFR (mGFR) and eGFR in pa-
tients with T2D and normal or mildly impaired renal
function (eGFR Modification of Diet in Renal Disease
[eGFRMDRD] 60 to 120 mL/min/1.73 m
2). SESTA-R estab-
lished that mean percentage changes in eGFR correlated
with true mGFR, and confirmed that the effect of aleglita-
zar therapy on SCr and GFR was non-progressive and re-
versible upon treatment discontinuation.
Data from SYNCHRONY and SESTA-R suggest good
short-term safety of aleglitazar in patients with normal
or mildly impaired kidney function and also provide evi-
dence for beneficial effects of aleglitazar on multiple
markers of CV risk, namely hyperglycemia, diabetic dys-
lipidemia, insulin resistance and inflammation [11]. To
assess the longer-term safety and efficacy of aleglitazar in
patients with T2D, additional trials were initiated, including
a renal safety study (AleNephro [NCT01043029]) and a
CV outcomes trial in patients with T2D following an acute
coronary syndrome (ACS; AleCardio [NCT01042769])
[12]. Although aleglitazar’s development was recently
halted due to lack of efficacy in CV outcomes indicating
no CV benefit, and PPAR-related class side effects in the
post-ACS T2D population [12], the renal effects of dualPPAR-α/γ activation remain of interest—in particular, the
development of another PPAR-α/γ agonist, tesaglitazar—
was terminated over concerns about the degree and poten-
tial lack of reversibility of elevations in SCr.
Here, we present the results of the Phase IIb AleNephro
study, which was designed to evaluate the renal effects of
aleglitazar treatment in patients with T2D and more ad-
vanced kidney impairment (stage 3 chronic kidney disease
[CKD]) using the PPAR-γ agonist pioglitazone as active
comparator over 52 weeks. Reversibility of renal effects




AleNephro was a randomized, double-blind, active-
controlled, parallel-group, multicenter Phase IIb renal
function non-inferiority safety study. Following a 2-week
screening period, patients received a once-daily dose
of 150 μg aleglitazar or 45 mg pioglitazone (Takeda
Pharmaceutical Company, Osaka, Japan) for 52 weeks,
added to pre-existing antihyperglycemic therapy and/or
diet and exercise. After termination of treatment, patients
were followed for 8 weeks, with visits in Weeks 4 and 8
to evaluate reversibility of renal effects.
Study population
Patients were recruited between May 27, 2010 and May
13, 2011. Enrolment was carried out by the principal in-
vestigator or designee at participating clinical sites. In-
clusion criteria were age ≥ 18 years, diagnosis of T2D
and moderately impaired kidney function (CKD stage 3,
as defined by eGFRMDRD ≥ 30 and < 60 mL/min/1.73 m
2),
plus the following at screening: naïve to the use of oral
antihyperglycemic agents or on monotherapy or combin-
ation therapy with no more than two antihyperglycemic
medications; HbA1c 6.5–10%; FPG ≤ 13.3 mmol/L; urinary
albumin/creatinine ratio (UACR) ≤ 3000 μg/mg; body mass
index from 25.0 kg/m2 (Asian patients: from 23.0 kg/m2)
to 35.0 kg/m2.
Exclusion criteria were: known diagnosis of renal dis-
ease (except diabetic nephropathy), congestive heart fail-
ure New York Heart Association class II to IV, known
macular edema or impaired liver function (alanine ami-
notransferase or aspartate aminotransferase > 3 times the
upper limit of normal). Patients were also excluded if
they were currently on, or had previously received, the
following treatments: thiazolidinedione or insulin (with
the exception of emergency cases, in which insulin was
given for < 7 consecutive days), or medications inter-
fering with measurement of creatinine (e.g. cimetidine,
trimethoprim, probenecid, sulfonamides, procaine or
thiazolesulfone); treatment with fibrates in the 3 months
preceding the screening visit; chronic therapy with a
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of prophylactic stable low-dose aspirin) 1 month prior to
screening; or changes in antihypertensive therapy in the
last 3 months or in statins in the last month before screen-
ing or likely to require changes during the study. All indi-
viduals provided written informed consent. The study was
conducted according to the principles of the Declaration
of Helsinki and the laws and regulations of the participat-
ing countries. The protocol was approved by independent
review committees or institutional review boards. A full
list of the ethics committees and institutional review
boards that approved the study is included in the supple-
mentary materials (Additional file 1: Table S1).
Randomization and masking
Patients, study site personnel and sponsor were all blinded
to treatment assignment. At the baseline visit, patients
were randomly assigned (via an interactive voice-response
system) in a 1:1 ratio to receive orally either 150 μg alegli-
tazar tablets and placebo capsules matching pioglita-
zone capsules, or 45 mg pioglitazone capsules and
placebo tablets matching aleglitazar tablets. The patient
randomization numbers were generated by Roche and
maintained by an unblinded statistician. The investigator
or designee entered the case report form number (CRF;
patient number) on the electronic CRF (given to a patient
at visit 2 at the time of randomization) and entered the
corresponding randomization number for allocation to
the treatment groups in the appropriate place on each
patient’s eCRF.
The patient randomization numbers were allocated se-
quentially in the order in which the patients were en-
rolled according to the specification document agreed
with the randomization company (S-Clinica).
The password-protected and/or encrypted electronic
master randomization list was kept in a central repository
by the Roche Biometrics and Drug Safety Departments.
No open key to the code was available at the study center,
to the Roche monitors, project statisticians, or to the pro-
ject team at Roche. Randomization was stratified by eGFR
values at screening < 45 versus ≥ 45 mL/min/1.73 m2. The
dose of 150 μg aleglitazar was selected based on the
Phase II dose-ranging study data, which demonstrated im-
provements in lipid and glycemic parameters with a favor-
able safety profile [9]. All medications were administered
once daily in the morning for 52 weeks, in addition to
pre-existing prescribed antihyperglycemic therapy and/or
diet and exercise management.
Study objective and endpoints
The primary objective of the study was to evaluate
changes in eGFR following 52 weeks of daily treatment
with 150 μg aleglitazar and 8 weeks’ follow-up observa-
tion after the last study medication, in comparison with45 mg pioglitazone. Secondary endpoints included per-
centage and absolute change from baseline in eGFR and
lipid profiles at end of treatment. Tertiary endpoints in-
cluded change from baseline to end of treatment and
after 8 weeks of follow-up in additional renal parame-
ters, and time to first occurrence of any component of
the triple-composite renal endpoint (end-stage renal dis-
ease [ESRD], confirmed doubling of SCr from baseline
[confirmed at least 4 weeks later] or confirmed increase
in SCr of 50% [confirmed within 1 week and leading to
discontinuation of treatment]), or the double-composite
renal endpoint (ESRD or any doubling of SCr from
baseline). Safety endpoints included adverse events, clin-
ical laboratory tests, electrocardiography, vital signs, phys-
ical examination, peripheral edema, and CV symptoms
including events adjudicated by an independent Clinical
Events Committee (CEC).
Procedures
Blood samples were taken at Weeks 2, 4, 8, 12, 16, 20,
26, 39, 52 (treatment period), 56, and 60 (follow-up) to
monitor renal, hematologic and biochemical parameters
and to assess glycemic control. Blood lipid parameters
were measured at baseline and again in Weeks 16, 26, and
52. First morning urine samples were collected at baseline,
Weeks 12, 26 and 52, and at both follow-up visits. Three
urine samples were collected for each data point: on the
morning of the visit and on two preceding mornings. Dip-
stick urine analysis was used to measure protein, glucose,
blood, pH, nitrites, and ketones at alternate visits. Safety
and tolerability were assessed throughout the study. All la-
boratory analyses were conducted at a central laboratory
(Covance Central Laboratory Services [Indianapolis, USA;
Geneva, Switzerland; and Singapore]). eGFR was calcu-
lated using the MDRD equation [13].
Statistical analysis
The primary analysis was non-inferiority of aleglitazar
to pioglitazone evaluated as a difference in percentage
change in eGFRMDRD from baseline to end of follow-up
(8 weeks after end of treatment). Protocol predefined
non-inferiority to pioglitazone was inferred if the lower
limit of the two-sided 95% confidence interval (CI) of
the difference in eGFR change was greater than –7.5%.
The margin of non-inferiority chosen (lower CI of the
difference of –7.5%) was considered to be clinically rele-
vant and was agreed by the Food and Drug Administra-
tion and European Medical Agency, taking into account
the inherent variability in creatinine levels and the antic-
ipated mean natural annual progression in GFR loss in
patients with T2D and CKD ranging from 0.9 up to
4 mL/min/1.73 m2 [14-16].
With a planned sample size of 150 patients enrolled per
treatment group (300 patients in total), it was expected
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out rate) per group would be included in the full analysis
set (FAS) population. This sample size of 132 patients per
group provided 80% power for testing the null hypothesis
for the primary variable (eGFR), using a one-sided α-level
of 0.025. As per protocol, the FAS, following an intent-to-
treat principle, consisted of all patients who were random-
ized, had at least one randomized study drug intake, and
had an evaluable baseline and at least one evaluable post-
baseline SCr measurement. Imputation using the last-
observation-carried-forward method was pre-specified at
the study design stage in the protocol as a simple and un-
ambiguous methodology and was hence carried out at the
analysis stage. The primary endpoint was assessed by ana-
lysis of covariance (ANCOVA) to determine the least
squares mean changes from baseline and 95% CI. The
ANCOVA model included the percentage change in eGFR
between baseline and end of follow-up as the dependent
variable and treatment, region, eGFR stratum, UACR
stratum (> 300 versus ≤ 300 μg/mg) as fixed effects with a
strata interaction term, and baseline eGFR as the covari-
ate. Equivalent ANCOVA models were used to calculate
percentage and absolute change for secondary and tertiary
endpoints to end of treatment or end of follow-up.
P-values are reported and values below 0.05 may be re-
ferred as nominally statistically significant. However, no
adjustment for multiplicity across secondary and tertiary
analyses was done. ANCOVA assumptions were examined
and for the endpoints that did not follow normal dis-
tribution (UACR, renin, aldosterone, urinary fractional
sodium excretion, alpha glutathione S-transferase [α-GST],
N-acetyl-β-D-glucosaminidase [NAG] and low-density
lipoprotein cholesterol), analysis was on a log-transformed
scale with dependent variable expressed as log of relative
change from baseline. In these cases, differences were
reverse-transformed and results were presented as the
percentage change in geometric means. Analogous re-
peated measures ANCOVA was used for descriptive ana-
lyses. Pre-specified subgroup analyses were done using
models as above, omitting the interaction term. In order
to avoid too few observations in each stratum, models
applied to change in UACR albuminuria subgroups were
further simplified by omitting fixed terms for region and
strata. The protocol pre-specified the last-observation-
carried-forward principle to account for missing values of
continuous variables. For end of follow-up endpoints,
last-observation-carried-forward was only applied where a
value was available at least 3 weeks after the last study
drug intake. The primary analysis population was the full
analysis population, using the intent-to-treat approach
(Figure 1). Safety analyses were carried out on the safety
population. Continuous variables defined in the protocol
as safety were analyzed on the safety population as abso-
lute change from baseline to end of treatment or endof follow-up using ANCOVA model as described for
primary endpoint. All analyses were done with SAS
(version 9.2) in UNIX.
Results
Patient disposition and baseline characteristics
AleNephro was conducted at 62 sites in 13 countries
across Europe, South America, Asia and Australia. Of
877 patients screened, 302 patients were randomized to
150 μg/day aleglitazar (n = 150) or 45 mg/day pioglita-
zone (n = 152) (Figure 1). Of these, 118 in each group
completed 52 weeks of the study treatment.
Baseline characteristics were well balanced (Table 1),
with patients in both treatment regimens having similar
baseline values for eGFR and UACR.
Although chronic therapy with non-steroidal anti-
inflammatory drug was an exclusion criterion, prophy-
lactic stable low dose of aspirin was permitted and aspirin
intake during study was recorded in approximately 42% of
patients in both treatment groups (Table 1).
Statistical analysis
Of the 302 patients enrolled into the study, 150 patients
were allocated to the aleglitazar group and 152 patients
to the pioglitazone group. Of these, four patients in the
pioglitazone group were excluded from the FAS because
of no evaluable post-baseline SCr measurement (n = 148),
and one patient in the aleglitazar group did not receive any
study medication, and so was also excluded (n = 149). Add-
itionally, 25 patients did not have evaluable SCr measure-
ments at least 3 weeks after last study drug intake (n = 9
on aleglitazar and n = 16 on pioglitazone). Therefore, 140
patients in the aleglitazar group and 132 in the pioglitazone
group were included in the primary analysis, providing at
least 80% power for the comparison.
Renal parameters
Mean percentage changes from baseline to end of
treatment and end of follow-up in renal function and
renin–angiotensin–aldosterone system (RAAS) markers,
including eGFR, SCr, cystatin-C, renin, aldosterone, urinary
fractional sodium excretion, α-GST and NAG, are summa-
rized in Table 2.
SCr showed an inverse pattern of change to eGFR at
the end of treatment and the end of follow-up. Increase
in mean cystatin-C occurred in both treatment groups
in parallel, with a greater increase in the aleglitazar
group at the end of treatment, but remained elevated at
the end of follow-up for both the aleglitazar and pioglit-
azone groups. Among other renal parameters investi-
gated, no differences were observed (p > 0.05) with the
exception of sodium excretion at the end of treatment,
where change from baseline was greater with aleglitazar
(p = 0.008).
Figure 1 Patient disposition and study populations. Safety analysis population: all patients who received at least one dose of the study drug.
Full analysis population: all patients who received at least one dose of study drug, and had an evaluable baseline and at least one evaluable
post-baseline measurement of serum creatinine. Completer population: all patients included in the full analysis population who completed
52 weeks of double-blind treatment. Per-protocol population: completers without major protocol violations (defined prior database lock and
unblinding). * 140 patients on aleglitazar and 132 patients on pioglitazone included in the full analysis population had at least one follow-up
measurement of serum creatinine≥ 21 days after last treatment intake, and therefore were included in the primary analysis.
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the aleglitazar group by Week 2 and plateaued after
8 weeks, returning towards baseline following cessation of
treatment (Figure 2A). Mean eGFR change at end of treat-
ment with aleglitazar was –15.0% (95% CI: –19.1, –10.8)
versus –5.4% (95% CI: –9.6, –1.2) with pioglitazone
(p < 0.001). The treatment difference in eGFR at end of
follow-up (the primary endpoint) was 0.77% (95% CI: –4.5,
6.0, p = 0.77), with lower 95% CI above –7.5%, thus estab-
lishing non-inferiority of aleglitazar versus pioglitazone.
The same pattern of changes was observed in both eGFR
strata (eGFR < 45 or ≥ 45 mL/min/1.73 m2) (Figure 2B).Absolute changes in eGFR from baseline to the end of
follow-up were also similar in aleglitazar versus pioglita-
zone groups irrespective of eGFR strata (Table 3). The
primary endpoint was met, irrespective of the analysis
population studied (Figure 3).
UACR
In the full analysis population, reductions in UACR of
35.0% with aleglitazar (95% CI: –46.8, –20.5) and 29.4%
with pioglitazone (95% CI: –42.4, –13.4) were observed
between baseline and end of treatment, and of 19.8%
with aleglitazar (95% CI: –36.3, 0.9) and 18.2% with
Table 1 Baseline characteristics and medication use
(full analysis population)





Age, years 66. 8 ± 8.0 68.2 ± 7.6
Women, n (%) 74 (50) 78 (53)
Race, white, n (%) 129 (87) 120 (81)
BMI, kg/m2 29.8 ± 3.3 29.8 ± 3.1
Median duration of diabetes, years 9.6 (0.4–40.2) 10.2 (0.2–48.2)
Systolic blood pressure, mmHg 130.5 ± 8.3 132.1 ± 10.4
Diastolic blood pressure, mmHg 77.6 ± 7.1 76.6 ± 8.7
Smokers, n (%) 8 (5) 4 (3)
Laboratory data*
HbA1c, % 7.5 ± 0.9 7.6 ± 0.9
FPG, mmol/L 8.5 ± 2.3 8.7 ± 2.2
Triglycerides, mmol/L 2.3 ± 1.6 2.2 ± 1.2
HDL-C, mmol/L 1.2 ± 0.3 1.2 ± 0.3
LDL-C, mmol/L 2.7 (2.1–3.4) 2.9 (2.3–3.5)
Markers of renal function
eGFR, mL/min/1.73 m2 46.5 ± 10.2 46.7 ± 10.2
SCr, μmol/L 123.6 ± 30.5 121.4 ± 29.2
Cystatin-C, μg/mL 1.2 ± 0.4 1.2 ± 0.3
UACR, mg/mmol† 2.0 (0.27–257.97) 1.9 (0.24–551.33)
Markers of RAAS
Renin, pmol/L 34.4 (17.8–130.5) 27.0 (17.8–87.0)
Aldosterone, pmol/L 194.2 (111.0–332.9) 194.2 (111.0–305.1)
Sodium excretion (fractional), % 1.5 (1.0–1.9) 1.5 (1.1–2.1)
Renal tubular markers
α-GST, μg/L 3.1 (3.1–3.1) 3.1 (3.1–3.9)
NAG, U/L 2.9 (1.6–4.7) 3.2 (1.8–5.1)
Baseline medication use, n (%)
Glycemic control treatment
Drug-naïve 6 (4) 7 (5)
Oral antidiabetic agents 143 (96) 141 (95)
Sulfonylurea 112 (75) 112 (76)
Metformin 87 (58) 95 (64)
Antihypertensive medication 138 (93) 140 (95)
Diuretics 73 (49) 81 (55)
ACE inhibitors and/or ARB 120 (81) 121 (82)
Statins 78 (52) 68 (46)
Aspirins‡§ 65 (44) 64 (43)
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker;
BMI = body mass index; eGFR = estimated glomerular filtration rate;
HbA1c = glycosylated hemoglobin; HDL-C = high-density lipoprotein cholesterol;
LDL-C = low-density lipoprotein cholesterol; RAAS= renin–angiotensin–aldosterone
system; SCr = serum creatinine; UACR = urine albumin-to-creatinine ratio.
*Mean ± standard deviation or median (interquartile range) unless otherwise
specified. †Minimum–maximum range quoted. ‡Aspirin, aspirin/diltiazem,
aspirin DL-lysine or salicylic acid. §Total number of patients who received at
least one treatment throughout the study.
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of follow-up. In patients with macroalbuminuria at baseline
(n = 48; > 80% of whom were on angiotensin-converting
enzyme inhibitors [ACEis] and/or angiotensin receptor
blockers [ARBs]), reductions in UACR of 59.3% with ale-
glitazar (95% CI: –76.6, –29.1) and 50.5% with pioglita-
zone (95% CI: –69.5, –19.5) were observed between
baseline and end of treatment (Figure 4). The effect of ale-
glitazar was maintained to end of follow-up, with 54.1%
(95% CI: –73.6, –20.2) reduction in UACR compared with
32.8% (95% CI: –58.5, 8.7) with pioglitazone.
Micro- and macroalbuminuria
At baseline, the majority of patients were categorized
to normoalbuminuria based on UACR (91/149 [61%]
aleglitazar versus 90/148 [61%] pioglitazone), followed by
microalbuminuria (37/149 [25%] aleglitazar versus 31/148
[21%] pioglitazone). Patients with macroalbuminuria at
baseline were 21/149 (14%) on aleglitazar versus 27/148
(18%) on pioglitazone. At the end of treatment, the follow-
ing shifts in categories from macroalbuminuria at baseline
were observed with aleglitazar and pioglitazone, respect-
ively: one patient (0.7%) and two patients (1.4%) from
macro- to normoalbuminuria; 11 patients (7.4%) and
seven patients (4.7%) from macro- to microalbuminuria;
eight patients (5.4%) and 17 patients (11.5%) remained
macroalbuminuremic. In both treatment groups, for
one patient (0.7%) with macroalbuminuria at baseline,
end-of-treatment status for macroalbuminuria was not
known.
Composite renal endpoints
One patient on aleglitazar and two patients on pioglita-
zone experienced the double composite renal endpoint
event, while four patients in each group reached the
triple composite renal endpoint event. No clinically rele-
vant differences were observed between the groups re-
garding the composite renal endpoints. No patients in
either group required acute dialysis, and one patient on
pioglitazone required chronic dialysis.
Lipid and glycemic parameters, body weight and blood
pressure
Superior improvements in lipids and similar changes in
glycemic control, body weight and blood pressure were
observed with aleglitazar versus pioglitazone at end of
treatment (Table 4).
General safety and tolerability
Adverse events were reported in 67% of patients on ale-
glitazar compared with 68% on pioglitazone. No major
safety concerns were identified. Selected adverse events
and adjudicated CV events are summarized in Tables 5
and 6, respectively. Congestive heart failure was reported
Table 2 Change in renal function and RAAS markers from baseline to end of treatment and follow-up
Parameter, LS mean percentage change (95% CI) EOT EOF
Aleglitazar Pioglitazone Aleglitazar Pioglitazone
150 μg 45 mg 150 μg 45 mg
eGFR n = 148 n = 147 n = 140 n = 132
–15.0† (–19.1, –10.8) –5.4 (–9.6, –1.2) –2.7 (–7.7, 2.4) –3.4 (–8.5, 1.7)
SCr n = 148 n = 147 n = 140 n = 132
17.3† (13.1, 21.5) 6.9 (2.6, 11.1) 5.4 (1.3, 9.5) 4.9 (0.7, 9.0)
Cystatin-C n = 148 n = 147 n = 140 n = 130
16.1‡ (11.8, 20.4) 11.4 (7.1, 15.8) 12.8 (8.7, 16.9) 14.8 (10.6, 19.1)
RAAS markers
Renin* n = 138 n = 138 n = 135 n = 127
19.9 (–1.8, 46.3) 31.0 (7.6, 59.5) 12.9 (–7.4, 37.7) 14.6 (–5.9, 39.6)
Aldosterone* n = 125 n = 122 n = 122 n = 114
–10.8 (–21.8, 1.7) –11.2 (–22.1, 1.2) –5.5 (–16.6, 7.1) 2.1 (–9.8, 15.6)
Sodium excretion (fractional)* n = 143 n = 139 n = 139 n = 130
27.1‡ (10.8, 45.9) 4.6 (–9.0, 20.3) 0.9 (–12.1, 15.8) –6.2 (–18.5, 8.0)
Renal tubular markers
α-GST* n = 96 n = 96 n = 84 n = 84
12.7 (0.7, 26.2) 1.0 (–10.0, 13.3) 3.9 (–7.6, 16.9) 6.9 (–5.1, 20.4)
NAG* n = 142 n = 140 n = 138 n = 132
12.4 (–7.7, 37.0) 0.2 (–17.8, 22.3) 1.7 (–14.4, 20.9) 6.8 (–10.3, 27.2)
Data are from the full analysis population. The last-observation-carried-forward principle was applied to missing values of continuous variables.
α-GST = α-glutathione S-transferase; CI = confidence interval; eGFR = estimated glomerular filtration rate; EOF = end of follow-up; EOT = end of treatment; LS = least
squares; NAG = N-acetyl-β-D-glucosaminidase; RAAS = renin–angiotensin–aldosterone system; SCr = serum creatinine.
*Analysis on log-transformed scale, geometric means ratio expressed as percentage change.
†p < 0.001 versus pioglitazone at EOT. ‡p < 0.05 versus pioglitazone at EOT.
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experienced at least one heart failure event positively
adjudicated by the CEC, two of which were reported as
serious adverse events and required hospitalization. Three
patients treated with pioglitazone experienced at least one
heart failure event, but none of these events were posi-
tively adjudicated by CEC.
Discussion
The AleNephro trial evaluated the reversibility of effects
of 52 weeks of treatment with aleglitazar as compared
with pioglitazone on renal parameters in patients with
T2D and moderate renal impairment (stage 3 CKD). As
expected for a PPAR-α agonist [17-19], aleglitazar was
associated with a reduction in eGFR during therapy that
was not progressive, plateauing after 8 weeks, and was
significantly greater than that of pioglitazone at end of
treatment. The principal finding of this study was that
the effects of both agents on renal function were revers-
ible, with a decrease in eGFR with aleglitazar that was
comparable (non-inferior) to that with pioglitazone by
8 weeks following withdrawal of treatment. Primary end-
point results were consistent using either the MDRD orthe Cockcroft–Gault equation for eGFR calculation (data
not shown). Furthermore, in patients with stage 3 CKD,
MDRD provides an approximately equivalent estimation
of eGFR compared with the CKD-Epi equation [20]. In
addition to meeting the primary endpoint, AleNephro
showed that the decrease in eGFR observed with aleglita-
zar during the treatment period reversed during follow-up
in patients with eGFR < 45 mL/min/1.73 m2. Hence, even
in this high-risk group, aleglitazar did not adversely affect
renal safety, similar to pioglitazone and fenofibrate [14,21].
These reversible changes in eGFR and SCr are consistent
with previous observations from SESTA-R [10] and con-
firm data from the AleCardio trial, which investigated the
effect of aleglitazar on cardiovascular outcomes after acute
coronary syndrome [12].
Although the mechanism of aleglitazar’s effect on eGFR
and SCr is unclear, the reversibility of the effect resem-
bles that of PPAR-α class of compounds, the fibrates,
and inhibitors of the RAAS system, on these renal
function markers, which paradoxically leads to reno-
protection rather than acute kidney toxicity [18,19,22].
For example, in the Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) trial, the increase in SCr
Figure 2 LS mean percentage change in eGFR. (A) Change from baseline over time (full analysis population). Last-observation-carried-forward
principle was applied to missing values of continuous variables. eGFR = estimated glomerular filtration rate; LS = least squares; EOT = end of treatment;
EOF = end of follow-up. (B) Change from baseline over time, by eGFR strata (full analysis population). Last-observation-carried-forward principle was
applied to missing values of continuous variables.
Table 3 Change in renal function from baseline in the overall cohort and by eGFR strata
Cohorts













Overall cohort n = 149 n = 148 n = 140 n = 148 n = 147 n = 132
46.5 –7.3 (–8.9, –5.6) –1.6 (–3.6, 0.4) 46.7 –2.8 (–4.5, –1.2) –1.7 (–3.7, 0.3)
eGFR < 45 mL/min/1.73 m2 n = 69 n = 68 n = 63 n = 59 n = 58 n = 52
37.7 –4.5 (–7.0, –2.0) 0.3 (–2.8, 3.4) 36.8 –0.8 (–3.4, 1.7) –0.3 (–3.5, 2.8)
eGFR≥ 45 mL/min/1.73 m2 n = 80 n = 80 n = 77 n = 89 n = 89 n = 80
54.2 –9.2 (–11.5, –6.9) –2.9 (–5.4, –0.2) 53.3 –4.3 (–6.5, –2.0) –2.5 (–5.1, 0.1)
Data show LS mean absolute changes to EOT and EOF observed in the full analysis population. The last-observation-carried-forward principle was applied to missing
values of continuous variables. CI = confidence interval; LS = least squares; EOT = end of treatment; EOF = end of follow-up.
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Figure 3 LS mean percentage change in eGFR from baseline at end of follow-up by analysis population. Circles = aleglitazar; squares =
pioglitazone. LS mean change from baseline and ± 95% CI. Analysis of covariance of percentage change from baseline. Missing data imputed using last-
observation-carried-forward principle applied only to follow-up measurements of serum creatinine≥ 21 days after last treatment intake. CI = confidence
interval; eGFR = estimated glomerular filtration rate; EOF = end of follow-up; EOT = end of treatment; LS = least squares. *Numbers reflect patients included
in the full analysis population who had at least one follow-up measurement of serum creatinine≥ 21 days after last treatment intake.
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treatment cessation and was accompanied by signifi-
cantly less decline in renal function (as measured by
eGFR) compared with placebo [19]. A meta-analysis com-
paring the effects of ACEi/ARB with other antihyperten-
sives demonstrated a consistent renoprotective effect of
ACEi/ARB over other antihypertensive drugs (and placebo)
in patients with T2D, independent of blood-pressure-
lowering effects [22].
The mechanism for eGFR reduction with PPAR-α ago-
nists is not well characterized. It may involve pre- orFigure 4 LS mean percentage change in UACR from baseline over tim
UACR values (interquartile range) were 75.4 mg/mmol (55.7–133.8) for a
(n = 27). Analysis on log-transformed scale, geometric means ratio expre
(using last-observation-carried-forward principle): n = 20 for aleglitazar an
and 25 for pioglitazone. LS = least squares; UACR = urine albumin-to-creapost-glomerular effects, including hemodynamic ef-
fects, or a combination of different mechanisms. Pre-
clinical studies have revealed that PPAR-α agonists
increase urinary fractional sodium excretion by decreas-
ing Na+-K+ATPase activity in the proximal tubule [23]
and altering cumulative sodium balance [24]. This is con-
sistent with the increase in urinary fractional sodium ex-
cretion seen during aleglitazar treatment in AleNephro,
which resolves during follow-up. Based on the effect
of PPAR-α on proximal tubular sodium handling, one
working hypothesis for the reduction of GFR observed ine (patients with macroalbuminuria at baseline). Median baseline
leglitazar (n = 21) and 89.6 mg/mmol (43.3–116.0) for pioglitazone
ssed as percentage change. Patients analyzed at end of treatment
d 26 for pioglitazone, and at end of follow-up: n = 19 for aleglitazar
tinine ratio.
Table 4 Change from baseline to end of treatment: lipids,








LDL-C* n = 142 n = 141
–7.3† (–13.2, –1.0) –0.3 (–6.8, 6.6)
HDL-C n = 142 n = 140
22.0‡ (17.4, 26.6) 11.6 (6.9, 16.3)
Triglycerides n = 142 n = 140








HbA1c, % n = 148 n = 147
–0.67 (–0.87, –0.48) –0.76 (–0.96, –0.56)
FPG, mmol/L n = 148 n = 147
–1.96 (–2.38, –1.54) –1.64 (–2.06, –1.22)
Body weight, kg n = 149 n = 147
2.4 (1.6, 3.2) 2.5 (1.7, 3.3)
Systolic blood pressure, mmHg n = 149 n = 147
1.7 (–1.0, 4.5) 2.3 (–0.4, 5.1)
Diastolic blood pressure, mmHg n = 149 n = 147
–2.2 (–3.9, –0.5) –0.5 (–2.3, 1.2)
Data show LS mean changes. The last-observation-carried-forward principle
was applied to missing values of continuous variables.
CI = confidence interval; FPG = fasting plasma glucose; HbA1c = glycosylated
hemoglobin; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density
lipoprotein cholesterol; LS = least squares.
*Analysis on log-transformed scale, geometric means ratio expressed as
percentage change.
†p < 0.05 versus pioglitazone at end of treatment. ‡p < 0.001 versus
pioglitazone at end of treatment.
Table 5 Selected adverse events (safety analysis population)






Peripheral edema 18 (12) 30 (20)
Heart failure (investigator-reported) 5 (3) 3 (2)
Fractures* 3 (2) 2 (1)
Renal AEs 8 (5) 6 (4)
Muscular AEs 4 (3) 5 (3)
Hepatic AEs 2 (1) 3 (2)
Hypoglycemia† 29 (20) 22 (15)
Severe hypoglycemia 2 (1) 0
Malignancy‡ 3 (2) 1 (1)
AE = adverse event.
*The fracture sites were ankle, foot and humerus for the aleglitazar cases and
clavicle, rib and scapula for the pioglitazone cases (one of the patients in the
pioglitazone group had two fractures).
†In both groups, approximately 90% of hypoglycemic events occurred in
patients on sulfonylureas. The total number of hypoglycemic events was 100
in the aleglitazar group and 56 in the pioglitazone group.
‡Malignancies were not considered to be related to study medication, including
one case of bladder cancer in the aleglitazar group with first symptoms reported
3 weeks after start of treatment. The other cases in the aleglitazar group related to
breast cancer and metastases to neck, and in the pioglitazone group to squamous
cell carcinoma of skin.
Table 6 Adjudicated cardiovascular events and
non-cardiovascular death (safety analysis population)











Non-fatal stroke 0 1*








*Non-fatal stroke and cardiovascular death occurred in the same patient, thus
total number of patients experiencing at least one MACE event was two in
aleglitazar group and three in pioglitazone group. The same patient has also
experienced a myocardial infarction, as judged by the investigator (not included
in the above summary), but insufficient information was provided to the Clinical
Events Committee to conclusively adjudicate this event as myocardial infarction
or unstable angina (cardiac enzymes data was not available). MACE = major
adverse cardiovascular events.
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induced hemodynamic changes. Elevated single-nephron
GFR is an unfavorable glomerular hemodynamic com-
pensatory mechanism for progressive nephron loss in pa-
tients with diabetic nephropathy [25]. Thus, lowering of
GFR by hemodynamic effects leading to lower capillary
pressure, which has been hypothesized for PPAR-α acti-
vation, may be protective.
In studies of ACEis and ARBs (e.g. RENAAL and
ONTARGET), an initial decline in eGFR is often ob-
served, most likely due to hemodynamic changes [26].
However, rather than being detrimental, this appears
to correlate with renal protection in the long term
[22,26-28]. For example, in the RENAAL trial, losartan
reduced UACR by 35%, associated with an 18% reduc-
tion in the rate of decline of renal function and 28% re-
duction in the risk of ESRD [27]. Assuming that the
physiology associated with the initial drop in eGFR is
similar across these different therapies, it may be specu-
lated that AleNephro data indicate possible renoprotection,with reductions in UACR of 30–35% observed with alegli-
tazar and pioglitazone at treatment end, similar to previous
UACR/proteinuria findings for pioglitazone [29,30]. In pa-
tients with baseline macroalbuminuria, > 80% of whom
were already on stable doses of ACEis and/or ARBs, UACR
decreased from baseline to treatment end by 59% with
aleglitazar and 50% with pioglitazone. The effect of ale-
glitazar on UACR in the range of proteinuria or very
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ation to end of follow-up. Clear evidence could only
come from a large clinical outcomes study with hard clin-
ical endpoints, which was beyond the scope of this renal
function study.
At the end of treatment, the renal marker cystatin-C
was elevated with aleglitazar relative to pioglitazone, al-
though the levels were comparable by end of follow-up.
This pattern in cystatin-C levels with aleglitazar is con-
sistent with the ACCORD renal study [31] and the
FIELD Helsinki substudy [32], which also showed an ini-
tial increase in cystatin-C during fenofibrate treatment
and reversibility following treatment discontinuation. A
contributing factor to elevations in cystatin-C may be
the anti-inflammatory effects of aleglitazar and pioglita-
zone, which can result in upregulation of cystatin-C syn-
thesis [33], but hemodynamic effects (as hypothesized
for SCr) may also drive cystatin-C changes. In terms of
the RAAS markers, in both treatment groups, renin
levels remained elevated at end of follow-up, while al-
dosterone was slightly reduced, although these changes
were not significant between treatment groups. As in
SESTA-R [10], elevations in the renal tubular markers
α-GST and NAG were observed with both aleglitazar
and pioglitazone; however, treatment differences were
not considered clinically significant.
No major safety concerns were identified with aleglita-
zar in AleNephro, and no increase in adverse events was
noted in patients with reduced eGFR compared with
previous studies. The incidence of edema was numerically
lower in patients treated with aleglitazar versus pioglita-
zone, although the incidence of investigator-reported con-
gestive heart failure events was higher in patients treated
with aleglitazar. However, the total number of adjudicated
CV events was similar between groups. The imbalance in
hypoglycemia events between the groups appears to be
largely driven by a subset of seven patients with multiple
(7–12) reported events accounting for 65 out of 100
events (versus three patients with six to eight events each
in the pioglitazone group accounting for 21 out of 56
events). In both groups, 90% of hypoglycemic events oc-
curred in patients on sulfonylureas.
The incidence of bone fractures was similar for alegli-
tazar and pioglitazone and none of the malignancy cases
were considered by the investigators to be drug related.
For the bladder cancer case in the aleglitazar group, first
symptoms were reported 3 weeks after treatment com-
menced, suggesting it was pre-existing and unlikely to
be treatment related, but detected due to the protocol-
imposed monitoring for this cancer.
Acknowledging possible deficiencies of the last-
observation-carried-forward method, the robustness of
the primary analysis was checked by performing two sen-
sitivity analyses using the per-protocol and completerspopulations. Both confirmed the conclusions of the pri-
mary analysis (data not shown). Only a small proportion
of observations available for the primary analysis was
missing (8.5%), and was therefore unlikely to have a large
impact on the interpretation of the results. Survival type
analyses were not performed for the primary endpoint as
they were not foreseen by the protocol. Also, the inter-
pretation of such analyses may be limited due to a poten-
tially small number of events.
AleNephro confirmed glycemia and lipid findings from
SYNCHRONY [9]. Aleglitazar (a balanced PPAR-α/γ
activator) was found to be similar to the PPAR-γ agonist
pioglitazone with respect to glycemic control (HbA1c
and FPG), but, presumably due to its activity on PPAR-α,
superior for control of atherogenic dyslipidemia.
Conclusions
In conclusion, AleNephro data indicated that aleglitazar-
induced reduction in eGFR plateaued after 8 weeks and
was significantly greater than that of pioglitazone at end of
52 weeks’ treatment. Following treatment withdrawal, the
decrease in eGFR caused by aleglitazar reversed and eGFR
values were comparable (non-inferior) to that with pioglita-
zone. Aleglitazar was generally well-tolerated, with similar
safety signals as pioglitazone treatment, although we
acknowledge that the small size of the study is a major limi-
tation regarding safety assessment. Even though aleglitazar’s
development program was halted due to lack of efficacy in
CV outcomes indicating no CV benefit and PPAR-related
class side effects in the post-ACS population following a
recent regular safety review of the AleCardio Phase III trial
[12], we believe that our findings provide important insights
into the renal effects of dual PPAR-α/γ activation.
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